This week’s China healthcare highlights from PharmaBoardroom content partner Selesta showcases strong innovation and global ambitions through major licensing deals, IPO activity, and clinical advancements. Notable transactions include Shimai Pharma’s Hong Kong IPO for its next-gen TCE platform, Mindray Medical’s IPO for global expansion, and transformative deals like Third Arc Bio-Adagene’s US$840M pact for tumor-specific T-cell engagers and SanegeneBio-Lilly’s US$1.2B RNAi collaboration. Clinical breakthroughs feature GenFleet’s Phase III KRAS G12D trial, Lepu Biopharma’s 75% ORR in r/r DLBCL, and AusperBio’s chronic hepatitis B success. Beijing Mabworks and Hygieia also delivered major milestones in PMN and cardiovascular therapies, further solidifying China’s leadership in innovative therapeutics and global biotech growth.
